A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes.

A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. Abstract Text:

Mikkael A Sekeres,Alex Z Fu,Jaroslaw P Maciejewski,Ali-Reza Golshayan,Matt E Kalaycio,Michael W Kattan,

BACKGROUND: The myelodysplastic syndromes (MDS) are divided into low-risk and high-risk diseases. Predictive models for response to growth factors (GF) have been developed based on red blood cell transfusion needs and erythropoietin levels. For low-risk MDS the optimal initial therapy (GF vs nongrowth factor [NGF] therapies, including differentiation and immunomodulatory agents) based on response rates to NGF and GF and survival, has not been defined. METHODS: A Markov decision analysis was performed on 799 low-risk MDS patients treated with either GF or NGF to determine the appropriate initial therapy. The treatment strategies analyzed included initial GF or NGF therapies, assuming 3 different states: Patients were either in the good GF predictive group (low transfusion needs and low erythropoietin levels), intermediate, or the poor GF predictive group (high transfusion needs and high erythropoietin levels). RESULTS: In the good GF predictive group, initial therapy with GF improved survival compared with NGF therapies at 3.38 years vs 2.57 years for a typical MDS patient. The advantage of GF to NGF was lost when NGF therapies produced a response in >or=46% of patients. In the intermediate or poor GF predictive groups, NGF maximized survival, provided response rates for NGF were >14% and 4%, respectively, for each predictive group. Quality of life adjustment did not alter the preferred strategy. CONCLUSIONS: Modeling estimates suggest that patients who fall into a good GF predictive group should almost always receive GF initially, whereas those in intermediate and poor predictive groups should almost always be treated with NGF.

A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. Publishing Authors By Initials

MA Sekeres,AZ Fu,JP Maciejewski,AR Golshayan,ME Kalaycio,MW Kattan,

For similar diagnosis: prognosis: treatment outcome research abstracts see: diagnosis: prognosis: treatment outcome research

PUBMED ID PMID:

MEDLINE DATE:

A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Cancer

VOLUME: 109

Page Numbers: 1125-32

Journal Abbreviation: Cancer

ISSN: 0008-543X

DAY: 15

MONTH: Mar

YEAR: 2007

A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 374236

A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. Keywords Mesh Terms:

KEYWORDS: Treatment Outcome

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. Information

Substance Name: Nerve Growth Factors

Registry Number: 0

Grant and Affiliation Information for A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes.

AFFILIATION: Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio 44195, USA. sekerem@ccf.org

Country: United States

AGENCY: United States NCRR

GRANT: U54RR19397-03

ACRONYM: RR

MEDLINETA: Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes Related Publications

• A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes.
• A nomogram for predicting 10-year life expectancy in men with prostate cancer after definitive therapy.
• An externally validated model for predicting long-term survival after exercise treadmill testing in patients with suspected coronary artery disease and a normal electrocardiogram.
• Angiographic confirmation of normal pleural thickness in right-upper-lobe collapse.
• Backward "displacement" of the spinolaminal line at C2: a normal variation.
• Child abuse and neglect: Perspective from King Faisal Specialist Hospital and Research Centre.
• Child abuse in Saudi Arabia: Report of ten cases.
• Childhood immunization in the Kingdom of Saudi Arabia.
• Editorial comment.
• Hydatid cysts in pancreas.
• Migration of central venous catheters.
• Minimally Invasive Therapy for Prostate Cancer: Use of Nomograms to Counsel Patients about the Choice and Probable Outcome of Therapy.
• Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma.
• Nomograms are difficult to beat.
• Predicting Prostate Cancer Behavior-What is a Urologist to Do?
• Predicting an optimal outcome after radical prostatectomy: the trifecta nomogram.
• Preoperative nomogram predicting 12-year probability of metastatic renal cancer.
• Prostate volume measured preoperatively predicts for organ-confined disease in men with clinically localized prostate cancer.
• Re: Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy gleason score (Partin Tables) based on cases from 2000 to 2005.
• Sarcoma nomogram: validation and a model to evaluate impact of therapy.
• Second colon cancer following Hodgkin's disease. A case report.
• Sitting on the fence in x-ray reporting.
• Systematic review of statistical methods used in molecular marker studies in cancer.
• The Use of Nomograms for Selecting BPH Candidates for Dutasteride Therapy.
• The addition of adrenaline to thoracic epidural meperidine does not improve analgesia following thoracotomy: [L'ajout d'adrenaline a la meperidine peridurale thoracique n'ameliore pas l'analgesie a la suite d'une thoracotomie].
• The effect of comorbidity and socioeconomic status on sexual and urinary function and on general health-related quality of life in men treated with radical prostatectomy for localized prostate cancer.
• The notched articular process of C7 (dorsalization of C7).
• The role of societal benefits and fairness concerns among decision makers and decision recipients.
• Two features of the atlas vertebra simulating fractures by tomography.
• [Not Available.]